Orchid Chemicals' stock ended with a gain of 9.95 per cent at Rs 53.60 -- its upper circuit limit on the BSE.
At the NSE, the scrip gained 9.95 per cent to Rs 53.60.
"... The CDR EG has issued the letter of approval dated March 10, 2014 and the Board of Directors of the company have approved the same today," the company had said in a filing to the BSE on Friday.
As per the terms of debt restructuring, the company will sell and transfer its Penicillin and Penems (including Carbapenems) API business together with its manufacturing facilities at Aurangabad, Maharashtra and associated research and development facility at Sholinganallur, Chennai, it said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
